Abstract Title:

Ocular hemorrhage possibly the result of HMG-CoA reductase inhibitors.

Abstract Source:

J Ocul Pharmacol Ther. 2004 Apr ;20(2):179-82. PMID: 15117574

Abstract Author(s):

F W Fraunfelder

Article Affiliation:

Casey Eye Institute, Oregon Health&Science University, Portland, OR 97201, USA. [email protected]

Abstract:

This retrospective case series describes the association between ocular hemorrhage and 3-hydroxy-3-methylglutaryl conenzyme A (HMG-CoA) reductase inhibitors (statins). The clinical characteristics of 95 case reports submitted to the World Health Organization (WHO), the Food and Drug Administration, and the National Registry of Drug-Induced Ocular Side Effects are summarized with classification of this ocular side effect according to WHO criteria. The average time to onset of ocular hemorrhage was 300 days with 11 positive dechallenge reports and 2 positive rechallenge cases. Some patients also received medications known to increase bleeding times. From the collected data, ocular hemorrhage is "possibly" due to statin therapy.

Study Type : Human: Case Report

Print Options


Key Research Topics

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2024 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.